Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | TEK | Q02763 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30052297 | 1.00 | HDAC6 (0.54) | HDAC6KDM4EALDH1A1HPGDADRA1A | |
| SCHEMBL28184787 | 0.81 | FGFR1 (0.45) | HDAC6KDM4EALDH1A1HPGDADRA1A | |
| SCHEMBL8839496 | 0.79 | HDAC6 (0.50) | HDAC6KDM4EALDH1A1HPGDADRA1A | |
| SCHEMBL8840058 | 0.78 | KDM4E (0.51) | HDAC6KDM4EALDH1A1HPGDADRA1A | |
| SCHEMBL3151968 | 0.78 | KDM4E (0.55) | HDAC6KDM4EALDH1A1HPGDADRA1A | |
| SCHEMBL14642669 | 0.77 | CDK1 (0.56) | HDAC6KDM4EALDH1A1HPGDADRA1A | |
| SCHEMBL8840050 | 0.77 | HSD17B10 (0.55) | HDAC6KDM4EALDH1A1HPGDADRA1A | |
| SCHEMBL28431107 | 0.76 | KDM4E (0.60) | HDAC6KDM4EALDH1A1HPGDADRA1A | |
| SCHEMBL469371 | 0.76 | HDAC6 (0.49) | HDAC6KDM4EALDH1A1HPGDADRA1A | |
| SCHEMBL4551666 | 0.76 | HDAC6 (0.46) | HDAC6KDM4EALDH1A1HPGDADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| EP-4125914-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115427044-A | Pyrrolopyrimidines as complement inhibitors | 拜奥克里斯特制药公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2021202977-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| US-8859490-B2 | Peptide nucleic acid monomers and oligomers | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-10-14 | — | — | US | disclosed |
| US-8859490-B2 | Peptide nucleic acid monomers and oligomers | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-10-14 | — | — | US | disclosed |
| US-20120065364-A2 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-03-15 | — | — | US | disclosed |
| US-20110245458-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHONOLOGICAL UNIVERSITY (SG) | 2011-10-06 | — | — | US | disclosed |
| WO-2010027326-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065364-A2 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | SIN3A, POLR2H, CYTH3 | HDAC6 2413/4885KDM4E 4577/4885ALDH1A1 4860/4885 |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | C5, C9, C1QBP | HDAC6 2412/4885KDM4E 3581/4885ALDH1A1 1325/4885 |
| US-20110245458-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | SIN3A, POLR2H, CYTH3 | HDAC6 2413/4885KDM4E 4577/4885ALDH1A1 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.